-
2024-510893-25-00
5
2025-04-29
Brain metastases of cancer > brain radionecrosis
-
2024-513053-69-00
5
2025-04-16
Moderately to Severely Active Crohn's Disease (CD)
-
2023-506601-19-00
6
2025-04-15
transplantation
-
2024-513084-38-00
9
2025-04-15
Recently diagnosed non favorable Acute Myeloid Leukemias
-
2023-504180-16-00
5
2025-04-07
Advanced Breast Cancer
-
2023-504904-26-00
5
2025-04-07
Progressive Pulmonary Fibrosis
-
2023-508507-20-00
5
2025-04-03
Locally advanced or metastatic conventional chondrosarcoma with an IDH
-
2024-511357-22-00
4
2025-03-31
Crohn's disease
-
2024-513550-30-00
5
2025-03-28
Newly diagnosed Glioblastoma
-
2024-512729-10-00
4
2025-03-27
Recurrent or metastatic solid cancer harboring a FGFR1,2 ,3 fusion/rea
-
2024-513862-20-00
5
2025-03-26
Chronic Rhinosinusitis with Nasal Polyposis
-
2023-505773-32-00
10
2025-03-25
Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer
-
2023-507937-14-00
7
2025-03-25
Metastatic Solid Tumor
-
2024-515861-33-00
4
2025-03-25
Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, an
-
2024-515307-19-00
1
2025-03-24
Advanced, or metastatic solid tumors with methylthioadenosine phosphor
-
2024-514594-21-00
5
2025-03-13
Heterozygous Familial Hypercholesterolemia
-
2024-513443-93-00
4
2025-03-10
Recurrent Meningioma without local treatment options (Surgery or Radio
-
2023-505291-30-01
4
2025-03-06
Triple Negative Breast Cancer with residual disease after neoadjuvant
-
2023-506803-25-01
10
2025-02-26
urgency
-
2023-510292-65-00
5
2025-02-25
chronic graft-versus-host disease
-
2024-516049-38-00
4
2025-02-18
CML-CP or CML-AP patients with T315I mutation
-
2023-509787-15-00
5
2025-02-17
Patients with localised prostate cancer and high-risk features of rela
-
2024-516044-25-00
10
2025-02-13
Migraines with aura
-
2023-506706-40-00
10
2025-02-11
Mantle-Cell Lymphoma